Skip to content

Study on the changes of SCFAs in fatty liver disease and their influence on the end products of classic inflammation pathways

Study on the changes of SCFAs in fatty liver disease and their influence on the end products of classic inflammation pathways

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044710
Enrollment
Unknown
Registered
2021-03-26
Start date
2018-05-01
Completion date
Unknown
Last updated
2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver disease

Interventions

Healthy Volunteer Group :No intervention
NAFL Group:No intervention
NASH Group:No intervention
NAFLD-related cirrhosis group :No intervention

Sponsors

The Sixth People's Hospital of Chengdu
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 71 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-70, no gender limit; 2. Based on medical history, imaging, biochemistry, and endoscopy results, in line with the 2016 NAFLD clinical practice guidelines diagnostic criteria of the European Society of Hepatology, Diabetes Society and Obesity Association; 3. Nearly 3 months No gastrointestinal bleeding, spontaneous peritonitis, hepatic encephalopathy and other acute complications related to portal hypertension; 4. Liver disease caused by viruses, alcohol, drugs and autoimmunity are excluded; 5. No fasting in the past 3 months.

Exclusion criteria

Exclusion criteria: 1. Complicated with serious diseases of heart, lung and other organ systems; 2. Malignant tumors or other wasting diseases; 3. Acute complications of portal hypertension occurred in the past 3 months; 4. Intestinal probiotics had been used in the past 3 months Bacteria or antibiotics, which may affect the results; 5. Rheumatic immune diseases or bacterial infections and other systemic inflammations in the past 3 months; 6. Co-infections and other serious diseases; 7. History of smoking or drinking; 8. History of infectious diseases Or viral hepatitis markers, autoantibodies are positive; 9. The subject requires withdrawal; 10. The researcher thinks it is necessary to exclude or not to continue participating in the research;

Design outcomes

Primary

MeasureTime frame
Blood acetic acid;Blood propionic acid;Butyric acid;

Countries

China

Contacts

Public ContactQian Xiang

The Sixth People's Hospital of Chengdu

sahuang2000@163.com+86 13882289947

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026